Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Therapeutics announced its Q4 and full-year 2025 financial results, highlighting progress toward a planned FDA New Drug Application submission for ALXN1840 to treat Wilson disease. The company strengthened its leadership team and balance sheet through a $91.9 million public offering, and reported reduced net losses compared to 2024. Additio…